Literature DB >> 32207804

Nonalcoholic Steatohepatitis: A Review.

Adam C Sheka1, Oyedele Adeyi2, Julie Thompson3, Bilal Hameed4, Peter A Crawford5, Sayeed Ikramuddin1.   

Abstract

Importance: Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression, development of cirrhosis, and need for liver transplant. Despite its importance, NASH is underrecognized in clinical practice. Observations: NASH affects an estimated 3% to 6% of the US population and the prevalence is increasing. NASH is strongly associated with obesity, dyslipidemia, type 2 diabetes, and metabolic syndrome. Although a number of noninvasive tests and scoring systems exist to characterize NAFLD and NASH, liver biopsy is the only accepted method for diagnosis of NASH. Currently, no NASH-specific therapies are approved by the US Food and Drug Administration. Lifestyle modification is the mainstay of treatment, including dietary changes and exercise, with the primary goal being weight loss. Substantial improvement in histologic outcomes, including fibrosis, is directly correlated with increasing weight loss. In some cases, bariatric surgery may be indicated to achieve and maintain the necessary degree of weight loss required for therapeutic effect. An estimated 20% of patients with NASH will develop cirrhosis, and NASH is predicted to become the leading indication for liver transplants in the US. The mortality rate among patients with NASH is substantially higher than the general population or patients without this inflammatory subtype of NAFLD, with annual all-cause mortality rate of 25.56 per 1000 person-years and a liver-specific mortality rate of 11.77 per 1000 person-years. Conclusions and Relevance: Nonalcoholic steatohepatitis affects 3% to 6% of the US population, is more prevalent in patients with metabolic disease and obesity, progresses to cirrhosis in approximately 20% of cases, and is associated with increased rates of liver-specific and overall mortality. Early identification and targeted treatment of patients with nonalcoholic steatohepatitis are needed to improve patient outcomes, including directing patients toward intensive lifestyle modification to promote weight loss and referral for bariatric surgery as indicated for management of obesity and metabolic disease.

Entities:  

Mesh:

Year:  2020        PMID: 32207804     DOI: 10.1001/jama.2020.2298

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  173 in total

1.  Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.

Authors:  Wenqi Yang; Ling Liu; Yuan Wei; Chunlu Fang; Shujing Liu; Fu Zhou; Yaping Li; Ge Zhao; Ziyi Guo; Yuan Luo; Liangming Li
Journal:  Lab Invest       Date:  2020-12-02       Impact factor: 5.662

2.  Chemotherapy-Associated Liver Injuries: Unmet Needs and New Insights for Surgical Oncologists.

Authors:  Luca Vigano; Martina Sollini; Francesca Ieva; Francesco Fiz; Guido Torzilli
Journal:  Ann Surg Oncol       Date:  2021-04-30       Impact factor: 5.344

3.  Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway.

Authors:  Ying Cao; Weili Mai; Rui Li; Shuwei Deng; Lan Li; Yanxi Zhou; Qiushi Qin; Yue Zhang; Xingang Zhou; Ming Han; Pu Liang; Yonghong Yan; Yu Hao; Wen Xie; Jie Yan; Liuluan Zhu
Journal:  Cell Mol Life Sci       Date:  2022-05-19       Impact factor: 9.261

4.  Evaluation of [18F]F-TZ3108 for PET Imaging of Metabolic-Associated Fatty Liver Disease.

Authors:  Peiyi Huang; Zhijun Li; Tukang Peng; Jihua Yang; Lei Bi; Guolong Huang; Yifan Qiu; Min Yang; Peizhen Ye; Mingxing Huang; Hongjun Jin; Liao Sun
Journal:  Mol Imaging Biol       Date:  2022-06-15       Impact factor: 3.488

Review 5.  Collaterals in portal hypertension: anatomy and clinical relevance.

Authors:  Hitoshi Maruyama; Shuichiro Shiina
Journal:  Quant Imaging Med Surg       Date:  2021-08

6.  Hepatic Steatosis: An Incidental Finding That Deserves Attention.

Authors:  Amy V Kontrick; Lisa B VanWagner; Chen Yeh; D Mark Courtney
Journal:  Acad Emerg Med       Date:  2020-12-15       Impact factor: 3.451

Review 7.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.

Authors:  Daniel Ferguson; Brian N Finck
Journal:  Nat Rev Endocrinol       Date:  2021-06-15       Impact factor: 43.330

8.  Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype.

Authors:  Flavia Noelia Mazzini; Frank Cook; John Gounarides; Sebastián Marciano; Leila Haddad; Ana Jesica Tamaroff; Paola Casciato; Adrián Narvaez; María Florencia Mascardi; Margarita Anders; Federico Orozco; Nicolás Quiróz; Marcelo Risk; Susana Gutt; Adrián Gadano; Celia Méndez García; Martin L Marro; Alberto Penas-Steinhardt; Julieta Trinks
Journal:  Metabolomics       Date:  2021-06-16       Impact factor: 4.290

Review 9.  COVID-19 in normal, diseased and transplanted liver.

Authors:  Alessandro Signorello; Ilaria Lenci; Martina Milana; Giuseppe Grassi; Leonardo Baiocchi
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

Review 10.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.